Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 

Liver disease, virologic response predict survival in cirrhotic HCC patients after RFA

10 Jan 2019

Virologic response and the severity of underlying liver disease predict long-term survival following radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) on cirrhosis, a recent study has shown.

Researchers enrolled 389 cirrhotic patients (median age 66 years; 76.6 percent male) who received RFA for HCC. Assessments were performed 1 month after RFA, every 3 months for the first 2 years and every 6 months for the following 2 years. Overall survival (OS), tumour recurrence and primary efficacy were among the study outcomes.

The primary efficacy rate of RFA was 86.1 percent; in 13.9 percent of the patients, more than one procedure was required to achieve complete ablation.

Median OS was determined to be 52.0 months; corresponding rates at 2, 5 and 10 years were 79.8 percent, 42.4 percent and 15.8 percent. Almost half of the deaths (49.5 percent) were related to HCC, while 24.0 percent of the deaths were due to liver disease, independent of HCC. The remaining 18.1 percent of deaths were due to nonliver-related causes.

Multivariate Cox proportional hazards regression models showed that age (hazard ratio [HR], 1.06; 95 percent CI, 1.04–1.08), a Child-Pugh score of B/C (HR, 2.75; 1.80–4.20) and gamma-glutamyl transferase levels >2N (HR, 1.53; 1.01–2.13) were all associated with an elevated risk of death. The same was true for alkaline phosphatase level >1.5N (HR, 2.68; 1.73–4.15).

In hepatitis C patients, OS was significantly longer in those who achieved a sustained virologic response relative to other patients (124.5 vs 49.2 months; p<0.001).  

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.